Affinity Asset Advisors’s CG Oncology CGON Stock Holding History

Affinity Asset Advisors’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.06M	Buy	+60,000	New	+$3.4M	0.21%	79

Other funds holding CGON

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Affinity Asset Advisors's CGON Position: Q1 2025 in Review

Affinity Asset Advisors sold out of CG Oncology (CGON) in Q1 2025, closing a stake of 100,000 shares — an estimated $2.87M sold.

Affinity Asset Advisors first reported a position in CGON in Q4 2024 and held it in 1 quarter. The position peaked at $2.87M in Q4 2024. 142 funds tracked by Wall St. Rank hold CGON as of Q1 2025.

Affinity Asset Advisors reported no remaining CG Oncology position as of Q1 2025 after selling out during the quarter.
Affinity Asset Advisors sold 100,000 CG Oncology shares in Q1 2025, an estimated $2.87M.
Affinity Asset Advisors first reported a position in CG Oncology in Q4 2024 and held it in 1 quarter.
Affinity Asset Advisors's CG Oncology position peaked at $2.87M in Q4 2024.
142 funds tracked by Wall St. Rank held CG Oncology as of Q1 2025.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.